<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603911</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000228</org_study_id>
    <nct_id>NCT04603911</nct_id>
  </id_info>
  <brief_title>RCT Comparing ESPB Solutions in Breast Surgery</brief_title>
  <official_title>An Investigator-Initiated, Double-Blind, Patient-Controlled, Randomized Control Trial Comparing the Effectiveness of Liposomal Bupivacaine to a Solution of Bupivacaine, Epinephrine Clonidine and Dexamethasone in Bilateral, Single Shot, Erector Spinae Plane Blocks During Oncoplastic Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of our research is to investigate the relative efficacy of liposomal bupivacaine&#xD;
      administered via an Erector Spinae Plane (ESP) block as compared to our standard of care&#xD;
      medication solution of (bupivacaine mixed with epinephrine, dexamethasone, and clonidine) for&#xD;
      pain management in subjects undergoing bilateral surgical intervention for breast cancer.&#xD;
      This will be an investigator-initiated, double-blind, patient-controlled, randomized control&#xD;
      trial comparing pain scores at 48 hours after injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain score will be recorded using a visual analogue scale (VAS) where 0 is no pain and 10 is unbearable pain.&#xD;
Pain will be recorded for the right and left side independently.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at 6, 12, 18, 24, 30, 38, 42, and 72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain score will be recorded using a visual analogue scale (VAS) where 0 is no pain and 10 is unbearable pain.&#xD;
Pain will be recorded for the right and left side independently.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm will receive standard of care solution for the ESPB block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.</description>
    <arm_group_label>Liposomal Bupivicaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine, epinephrine, dexamethasone, and clonidine</intervention_name>
    <description>The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Standard Preparation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults 18 to 75 years of age at screening&#xD;
&#xD;
          2. Scheduled to undergo oncoplastic bilateral mastectomy and reconstruction surgery at&#xD;
             Tufts Medical Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Adults unable to consent (inability to read, write, or has some impairment that&#xD;
             hampers consent process or documentation, or cognitively impaired adults)&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Pregnant minors&#xD;
&#xD;
          4. Woman of childbearing potential who are unwilling or unable to complete a pregnancy&#xD;
             test&#xD;
&#xD;
          5. Minors i.e., individuals who are not yet adults (neonates, children, teenagers)&#xD;
&#xD;
          6. Wards of the state&#xD;
&#xD;
          7. Non-viable neonates&#xD;
&#xD;
          8. Neonates of uncertain viability&#xD;
&#xD;
          9. Prisoners&#xD;
&#xD;
         10. Adults with known allergy, hypersensitivity, intolerance or contraindication to study&#xD;
             medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sean Gallagher, MD</last_name>
    <phone>(617) 636-4526</phone>
    <email>sgallagher@tuftsmedicalcenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sean Gallagher, MD</last_name>
    <phone>617636-4526</phone>
    <email>sgallagher@tuftsmedicalcenter.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Gallagher, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bilateral breast surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

